VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ZTS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ZTSZoetis Inc.
$76.29$32.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

ZTS logoZoetis Inc.(ZTS)Earnings, Financials & Key Ratios

ZTS•NYSE
$76.29
12.7× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryAnimal health pharmaceuticals and vaccines
AboutZoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.Show more
  • Revenue$9.47B+2.3%
  • EBITDA$4.08B+5.0%
  • Net Income$2.67B+7.5%
  • EPS (Diluted)6.02+10.1%
  • Gross Margin70.49%+2.0%
  • EBITDA Margin43.14%+2.7%
  • Operating Margin38%+3.7%
  • Net Margin28.23%+5.1%
  • ROE65.99%+29.6%

ZTS Price & Volume

Zoetis Inc. (ZTS) stock price & volume — 10-year historical chart

Loading chart...

Revenue Deceleration Challenges Premium Valuation Multiples

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Decelerating
Profitability:Strong
Financial:Strained
Cash Flow:Mixed
Primary Risk:Rising leverage and debt

Key Thesis Takeaways

  • Zoetis faces a critical inflection point as top-line growth has decelerated to 1.9% in 2026Q1, signaling that post-pandemic demand tailwinds have largely faded.
  • While the company maintains a robust 71.7% gross margin, aggressive capital allocation—including $2.1 billion in 2025Q4 share repurchases—has significantly eroded the equity base to $3.2 billion.
  • Investors should monitor whether the current 11.01 forward P/E ratio can be sustained as operating margins compress to 36.3% and financial leverage climbs to a 2.86 debt-to-equity ratio.

Verdict Logic

while the stock trades at a 11.01 forward P/E, the combination of decelerating 1.9% revenue growth and a 40% contraction in equity since 2025Q3 warrants a cautious wait-and-see approach.

ZTS Growth Metrics

Zoetis Inc. (ZTS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years7.11%
5 Years7.24%
3 Years5.42%
TTM2.4%

Profit CAGR

10 Years22.94%
5 Years10.29%
3 Years8.13%
TTM4.96%

EPS CAGR

10 Years24.37%
5 Years11.97%
3 Years10.27%
TTM8.26%

Return on Capital

10 Years24.41%
5 Years26.58%
3 Years28.18%
Last Year29.9%

ZTS Recent Earnings

Zoetis Inc. (ZTS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$1.53-4.4%
$1.60
Rev
$2.3B-1.7%
$2.3B
Q1 2026
Feb 12, 2026
Metric
Actual
Est
EPS
$1.48+5.7%
$1.40
Rev
$2.4B+1.1%
$2.4B
Q4 2025
Nov 4, 2025
Metric
Actual
Est
EPS
$1.70+4.9%
$1.62
Rev
$2.4B-0.4%
$2.4B
Q3 2025
Aug 5, 2025
Metric
Actual
Est
EPS
$1.76+8.6%
$1.62
Rev
$2.5B+2.1%
$2.4B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$1.53vs $1.60-4.4%
$2.3Bvs $2.3B-1.7%
Q1 2026Feb 12, 2026
$1.48vs $1.40+5.7%
$2.4Bvs $2.4B+1.1%
Q4 2025Nov 4, 2025
$1.70vs $1.62+4.9%
$2.4Bvs $2.4B-0.4%
Q3 2025Aug 5, 2025
$1.76vs $1.62+8.6%
$2.5Bvs $2.4B+2.1%
Based on last 12 quarters of dataView full earnings history →

Latest ZTS News

Recent stock market news and headlines for Zoetis Inc. (ZTS)

PRNewsWire·1 day ago
Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTS

LOS ANGELES, July 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zoetis Inc. ("Zoetis" or "the Company") (NYSE: ZTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ZTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

PRNewsWire·Jun 29, 2026
Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTS

LOS ANGELES, June 29, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zoetis Inc. ("Zoetis" or "the Company") (NYSE: ZTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ZTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Peers Comparison

Key metrics vs top competitors for Zoetis Inc. (ZTS)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ZTS logoZTSZoetis Inc.Current
$76.29$31.98B12.672.28%28.23%65.99%2.63%
ELAN logoELANElanco Animal Health Incorporated
$24.64$12.31B-52.436.22%-4.95%-3.64%—
PCRX logoPCRXPacira BioSciences, Inc.
$25.82$1.02B161.383.63%1.27%1.31%—
PAHC logoPAHCPhibro Animal Health Corporation
$33.12$1.34B27.8327.37%6.35%29.49%—
IDXX logoIDXXIDEXX Laboratories, Inc.
$570.25$45.29B43.6010.42%24.63%70.87%—
NEOG logoNEOGNeogen Corporation
$9.39$2.04B-1.87-3.2%-69.93%-29%—

Compare ZTS vs Peers

Zoetis Inc. (ZTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ELAN

Most directly comparable listed peer for ZTS.

Scale Benchmark

vs LLY

Larger-name benchmark to compare ZTS against a more recognizable public peer.

Peer Set

Compare Top 5

vs ELAN, PCRX, PAHC, IDXX

ZTS SEC Filings & Documents

Zoetis Inc. (ZTS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Feb 12, 2026·SEC

Material company update

Feb 5, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 12, 2026·SEC

FY 2025

Feb 13, 2025·SEC

10-Q Quarterly Reports

4
FY 2026

May 7, 2026·SEC

FY 2025

Nov 4, 2025·SEC

FY 2025

Aug 5, 2025·SEC

Get notified when ZTS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ZTS Frequently Asked Questions

Zoetis Inc. (ZTS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Zoetis Inc.'s revenue?

Zoetis Inc. (ZTS) reported $9.51B in revenue for fiscal year 2025. This represents a 165% increase from $3.58B in 2010.

How fast is Zoetis Inc. growing?

Zoetis Inc. (ZTS) grew revenue by 2.3% over the past year. Growth has been modest.

Is ZTS profitable?

Yes, Zoetis Inc. (ZTS) is profitable, generating $2.64B in net income for fiscal year 2025 (28.2% net margin).

Dividend & Returns
Does ZTS pay dividends?

Yes, Zoetis Inc. (ZTS) pays a dividend with a yield of 2.63%. This makes it attractive for income-focused investors.

What is ZTS's return on equity?

Zoetis Inc. (ZTS) has a return on equity (ROE) of 66.0%. This is excellent, indicating efficient use of shareholder capital.

What is Zoetis Inc.'s free cash flow?

Zoetis Inc. (ZTS) generated $2.14B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in ZTS back in 2010?

Total return calculator · dividends reinvested · 16+ years of data

See returns →